首页> 外国专利> Pharmaceutical composition for repairing a vascular injury comprising a chemotactic hematopoietic stem cell product comprising mononuclear cells enriched for cd34+ cells, method of preparing the pharmaceutical composition and use thereof in the preparation of a medicament

Pharmaceutical composition for repairing a vascular injury comprising a chemotactic hematopoietic stem cell product comprising mononuclear cells enriched for cd34+ cells, method of preparing the pharmaceutical composition and use thereof in the preparation of a medicament

机译:用于修复血管损伤的药物组合物,其包括趋化性造血干细胞产物,其包含富含cd34 +细胞的单核细胞,其制备方法及其在药物制备中的用途

摘要

A sterile pharmaceutical composition is disclosed for repairing a vascular injury caused by vascular insufficiency. The composition comprises: (a) a vascular injury-repairing amount of a sterile chemotactic hematopoietic stem cell product, the vascular injury-repairing amount being effective to repair a vascular injury caused by vascular insufficiency, the chemotactic hematopoietic stem cell product comprising a nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells, which further contains a subpopulation of potent CD34+ cells that express CXCR-4 and that have CXCR-4-mediated chemotactic activity, and (b) a stabilizing amount of serum, wherein the stabilizing amount of serum is greater than 20% (v/v), wherein the pharmaceutical composition is further characterized as having the following properties for at least 24 hours following acquisition of the chemotactic hematopoietic stem cell product when tested in vitro after passage through a catheter: (i) at least 70% of CD34+ cells, (ii) contains a subpopulation of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity; (iii) is at least about 70% viable; and (iv) is able to form hematopoietic colonies in vitro.
机译:公开了用于修复由血管功能不全引起的血管损伤的无菌药物组合物。组成包括:(a)无菌趋化性造血干细胞产物的血管损伤修复量,该血管损伤修复量可有效修复由血管功能不全引起的血管损伤,该趋化性造血干细胞产物包含自体未扩增的分离群体富含CD34 +细胞的单核细胞,其中进一步包含表达CXCR-4并具有CXCR-4介导的趋化活性的有效CD34 +细胞的亚群,以及(b)稳定量的血清,其中稳定量大于20%(v / v),其中所述药物组合物的特征还在于,在通过导管后进行体外测试时,获得趋化性造血干细胞产物后至少24小时具有以下特性:(i)至少70%的CD34 +细胞,(ii)包含具有CXCR-4介导的趋化活性的有效CD34 + / CXCR-4 +细胞的亚群;(iii)至少约70%可行;和(iv)能够在体外形成造血菌落。

著录项

  • 公开/公告号IL191277A

    专利类型

  • 公开/公告日2014-06-30

    原文格式PDF

  • 申请/专利权人 AMORCYTE INC.;

    申请/专利号IL20080191277

  • 发明设计人

    申请日2008-05-06

  • 分类号C12N5/0789;

  • 国家 IL

  • 入库时间 2022-08-21 15:57:58

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号